# PROGNOSTIC MODELING AND OUTCOME PREDICTION IN PEDIATRIC PATIENTS WITH ACUTE RESPIRATORY VIRAL INFECTIONS COMPLICATED BY PNEUMONIA

***Sh.Kh Pulatova, U.S Saifiddinov***

*Affiliation: Abu Ali ibn Sino Bukhara State Medical Institute*

*City: Bukhara, Uzbekistan*

**Abstract:** Acute respiratory viral infections (ARVI) are the most frequent cause of medical visits in pediatrics, yet their progression to secondary bacterial or severe viral pneumonia remains a leading cause of childhood mortality worldwide. Early prediction of disease outcomes is critical for risk stratification and the optimization of therapeutic interventions. This article examines the multifaceted approach to forecasting outcomes in children, integrating clinical indicators, laboratory biomarkers, scoring systems, and advanced imaging. By synthesized current data, we provide a framework for identifying high-risk patients who may require intensive care escalation.

**Key words:** Acute respiratory viral infections, viral pneumonia

## 1. Introduction

The interplay between viral pathogens and the pediatric host is complex. While most ARVI cases follow a self-limiting course, a significant subset of children develops secondary pneumonia. This complication accounts for approximately **15% of all deaths** in children under five years of age globally. The challenge for clinicians lies in the "prognostic window"—the period where a simple infection transitions into a life-threatening condition. [1.3]Accurate prediction during this phase can reduce hospital stays, prevent invasive procedures, and lower mortality rates.

## 2. Patient-Related and Clinical Predictors

Predictive modeling begins with the baseline characteristics of the patient. Factors such as age and pre-existing conditions serve as the foundation of the

prognostic profile. [10]

**2.1 Age and Developmental Vulnerability**

Infancy (age < 12 months) is the most significant independent predictor of a severe outcome. The narrow diameter of the airways, horizontal orientation of the ribs, and an immature immune response (specifically low levels of IgA) increase the risk of air trapping and rapid desaturation. [4.5]

**2.2 Respiratory and Vital Sign Dynamics**

Clinical stability is monitored through dynamic assessment. The following are considered "Red Flags" for poor prognosis: [6.9.11.14]

- **Refractory Fever:** Fever > 39 circ C persisting for more than 48 hours after the initiation of antibiotics.
- **Hypoxemia:** An $SpO2 < 92% on room air is highly predictive of the need for mechanical ventilation. [17.18]
- **Respiratory Effort:** Severe subcostal and intercostal retractions (chest indrawing) and nasal flaring indicate a high work of breathing that may lead to respiratory muscle exhaustion.

**3. Laboratory Biomarkers: The "Gold Standard" of Prediction**

In 2024-2025, the focus has shifted toward a "multi-biomarker" approach. Relying on a single test often leads to false negatives, whereas a combination provides high sensitivity. [12.15.18]

**3.1 Procalcitonin (PCT) and C-Reactive Protein (CRP)**

- **PCT:** Remains the most specific marker for bacterial secondary infection. Levels > 0.5 ng/mL suggest bacterial involvement, while levels > 2.0 ng/mL are strongly associated with septic shock and intensive care unit (ICU) admission. [20. 22. 23]
- **CRP:** A non-specific but useful marker. Levels exceeding **80–100 mg/L** within the first 24 hours of pneumonia diagnosis are correlated with the development of parapneumonic effusions and empyema. [25. 26]

**3.2 Advanced Indicators**

Recent studies have highlighted the **Neutrophil-to-Lymphocyte Ratio**

**(NLR)**. An NLR > 5.0 at the time of admission is an early warning sign of a dysregulated inflammatory response, often seen in necrotizing pneumonia. Additionally, low serum **Albumin** levels (< 30 g/L) have been identified as a predictor of prolonged hospitalization and the need for pleural drainage. [19]

### 4. Scoring Systems for Risk Stratification

Standardized scores allow for objective communication between departments (Emergency vs. ICU).

| Score System | Key Parameters | Outcome Prediction |
|---|---|---|
| **PEWS (Pediatric Early Warning Score)** | Behavior, Cardiovascular, Respiratory | Predicts clinical deterioration in general wards. |
| **P-SIRS** | Temp, Heart Rate, Respiratory Rate, WBC | Identifies the onset of Systemic Inflammatory Response Syndrome. |
| **qSOFA (Pediatric)** | Altered Mental Status, Systolic BP, Respiratory Rate | Predicts high mortality risk in suspected sepsis cases. |

### 5. Radiological and Ultrasound Forecasting

While the traditional Chest X-ray (CXR) is standard, **Lung Ultrasound (LUS)** has emerged as a superior prognostic tool in pediatric practice.

- **Consolidation Size:** Areas of consolidation > 2 cm detected by ultrasound are associated with a higher probability of bacterial co-infection.
- **B-line Patterns:** The presence of "confluent B-lines" suggests interstitial edema, often seen in viral-driven ARDS (Acute Respiratory Distress Syndrome).

- **Early Effusion Detection:** Ultrasound can detect pleural fluid as small as **5–10 mL**, allowing for earlier intervention than CXR, which usually requires > 50 mL for visualization.

**6. Long-Term Outcomes and Sequelae**

Predicting the outcome is not limited to the acute phase; it includes the risk of chronic lung disease.

1. **Bronchiectasis:** Common in children who survive necrotizing pneumonia or severe Adenovirus infections.
2. **Restrictive Lung Disease:** Scarring from severe pneumonia can limit lung expansion, leading to a permanent decrease in forced vital capacity (FVC).
3. **Asthma Development:** Severe RSV or Rhinovirus pneumonia in early childhood is a known risk factor for the development of reactive airway disease later in life. [24.25]

**7. Conclusion**

The prognosis for a child with ARVI complicated by pneumonia depends on the timely synthesis of clinical, biochemical, and imaging data. The most accurate predictive model for 2025 involves the integration of:

1. **Clinical monitoring** (respiratory rate and SpO2).
2. **Biomarker kinetics** (PCT and CRP trends).
3. **Point-of-care ultrasound (POCUS)** for real-time visualization of lung tissue recovery.

Early identification of high-risk profiles allows for the targeted use of advanced therapies (e.g., high-flow nasal cannula, surfactant therapy, or immunomodulators), ultimately improving the survival and quality of life for pediatric patients.

## *REFERENCE*

1. Пулатова, Ш. Х. (2021). АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ И ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ: КОМОРБИДНОСТЬ КАК ФАКТОР РИСКА НЕДОСТАТОЧНОЙ

ЭФФЕКТИВНОСТИ ТЕРАПИИ. In *АКТУАЛЬНЫЕ ВОПРОСЫ МЕДИЦИНЫ КРИТИЧЕСКИХ СОСТОЯНИЙ* (pp. 59-60).

2. Усмонов, У. Р., & Иргашев, И. Э. (2020). Changes in the morphofunctional properties of thymus and spleen under the influence of mites of different origins. Новый день в медицине, (2), 242-244.

3. Влияние вентиляции легких, контролируемой по объему и по давлению, на результаты лечения больных с геморрагическим инсультом / А.И. Грицан, А.А. Газенкампф, Н.Ю. Довбыш, А.В. Данилович // Вестник анестезиологии и реаниматологии. — 2012. — № 3. — С.26—31.

4. Rizoyevich, U. U., Olimjonovich, J. O., Khusenovich, S. S., & Sharifboevna, K. D. (2021). Changes in the morphofunctional properties of thymus, spleen and lymphoid systemunder the influence of mites of different origins. Web of Scientist: International Scientific Research Journal, 2(12), 533-540.

5. Пулатова, Ш. Х., Азимов, Б. К., & Тоиров, И. Р. (2019). Эндоваскулярное лечение больных ишемической болезнью сердца. *Евразийский кардиологический журнал*, (S1), 327-328.

6. Rizoyevich, U. U., Olimjonovich, J. O., Khusenovich, S. S., & Sharifboevna, K. D. (2022). CHANGES IN THE MORPHOFUNCTIONAL PROPERTIES OF THYMUS, SPLEEN AND LYMPHOID SYSTEMUNDER THE INFLUENCE OF MITES OF DIFFERENT ORIGINS. Web of Scientist: International Scientific Research Journal, 3(1), 23-29.

7. Байханова, М. Б., Бафаев, Ж. Т., & Пулатова, Ш. Х. (2009). Роль врача общей практики в повышении медицинской грамотности населения. *Врач-аспирант*, *28*(1), 48-50.

8. Khayotovich, K. D., & Ikromovich, T. I. (2022). SPECIFICITY OF RESUSCITATION MEASURES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARRHYTHMIA. World scientific research journal, 10(1), 150-155.

9. Хайитов, Д. Х., & Болтаев, Э. Б. (2022). ПОСТРЕАНИМАЦИОН

КАСАЛЛИК НАТИЖАСИДА КЕЛИБ ЧИКАДИГАН АСОРАТЛАРНИ БАРТАРАФ ЭТИШДА ЗАМОНАВИЙ ИНТЕНСИВ ТЕРАПИЯ. КЛИНИК АМАЛИЕТДА УЧРАГАН ХОЛАТ. *Academic research in modern science*, *1*(9), 172-178.

10. Khayotovich, K. D., & Ikromovich, T. I. (2022). Specific Morpho functional Changes of the Lymphatic System in Patients Suffering from Burns. Eurasian Research Bulletin, 15, 81-84.

11. Yarashev A.R., Boltaev E.B., Shabaev Y.K. A retrospective analysis of complications of percutaneous dilated tracheostomy // New day in medicine, 2020. 4 (32). P. 301-304.

12. Khayotovich, K.D., & Bekmurodugli, B.E. (2022). Case in clinical practice: Modern intensive care in the treatment of post-resuscitation complications caused by cardiac arrhythmias. *ACADEMICIA: An International Multidisciplinary Research Journal*.

13. Babanazarov, U. T., & Barnoyev, S. S. (2023). Clinical Characteristics of Patients with Chronic Diffuse Liver Disease Against the Background of Covid-19. *Genius Repository*, *26*, 49-55.

14. Rizaeva, M. Z. (2022). The clinical course of atrial fibrillation in patients with coronary heart disease. European journal of molecular medicine, 2(1).

15. Turobkulovich, B. U., & Khayotovich, K. D. (2024). MORE THAN MINIMUM CONSCIOUSNESS: APPALLIC SYNDROME. *European Journal of Interdisciplinary Research and Development*, *23*, 113-115.

16. Ризаева, М. Ж. (2020). ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ЭЛЕКТРИЧЕСКОЙ КАРДИОВЕРСИИ ПРИ ПЕРСИСТИРУЮЩЕЙ ФОРМЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Новый день в медицине, (4), 322-325.17. Потапов А.А., Крылов В.В., Лихтерман Л.Б. и др. Современные рекомендации по диагностике и лечению тяжелой черепно-мозговой травмы // Журнал вопросы нейрохирургии. – 2006. – № 1. – С. 3–8.

18. Qoyirov, A. Q., Kenjaev, S. R., & Xaitov, S. S. (2020). Egamova NT, Boltaev EB The role of delirium in patients with myocardial infarction of

complicated acute heart failure. *New Day in Medicine*, *3*(31), 68-71.

19. Kh, P. S., & Ganiev, N. S. (2022). The Importance of Cardioprotective Artificial Ventilation of The Lungs in Intensive Care. Eurasian Research Bulletin, 15, 208-212.

20. Эшонов, О. Ш., & Болтаев, Э. Б. (2020). СПОСОБ ЭКСТРЕННОГО ОПРЕДЕЛЕНИЯ СТЕПЕНИ ТЯЖЕСТИ ЭНДОТОКСИКОЗА ПРИ НЕОТЛОЖНИХ СОСТОЯНИЯХ. *Новый день в медицине*, (1), 462-464.

21Sharifovich, B. S., & Xayotovich, X. D. (2023). Management Of Deep Vein Thrombosis. *Genius Repository*, *27*, 59-71.

22. Ураков, Ш. Т., & Ризаева, М. Ж. (2019). КЛИНИЧЕСКИЙ СЛУЧАЙ ПАЦИЕНТА С СИНДРОМОМ МАРФАНА. Новый день в медицине, (4), 439-440.

23. Мирзажонова, Г. С., Пулатова, Ш. Б., & Набиева, Д. А. (2023). *Частота поражения сердца при анкилозирующем спондилите* (Doctoral dissertation, Zamonaviy tibbiyotning dolzarb muammolari yosh olimlar xalqaro anjumani, Uzbekiston).

24. Бабаназаров, У. Т., & Хайитов, Д. Х. (2024). БОЛЬШЕ, ЧЕМ МИНИМАЛЬНОЕ СОЗНАНИЕ: АПАЛЛИЧЕСКИЙ СИНДРОМ. *European Journal of Interdisciplinary Research and Development*, *23*, 109-112.

25. Sh, B. S. (2024). IMPORTANCE OF MYORELAXATION IN PATIENTS WITH SEVERE COMA. *Journal of new century innovations*, *47*(3), 5-8.

26. Babanazarov, U. T., & Barnoyev, S. S. (2023). Clinical Characteristics of Patients with Chronic Diffuse Liver Disease Against the Background of Covid-19. *Genius Repository*, *26*, 49-55.

27. Barotov Sh.K. (2024). NEUROPROTECTION AND NEUROINTERVENTION IN INTENSIVE CARE: STRATEGIES FOR PROTECTING NERVOUS TISSUE IN CRITICALLY ILL PATIENTS. *World Scientific Research Journal*, *34*(2), 154-157.